Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Webcasts|September 24, 2019
The Product Development Superhighway: Leveraging End-to-End Solutions for Market Success
Author(s)Catalent
Join experts for a discussion on how contracting with a single service provider can offer significant benefits to the customer. Live: Tuesday, Sept. 24, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Sept. 24, 2020 Register free
Register free:
Event Overview:
Pharmaceutical and biotechnology companies value streamlined services from early-phase development to clinical supply services to commercialization. These services can not only provide improved efficiencies, such as the ease of transition from one development phase to the next, but also remove the challenges of dealing with multiple vendors when transitioning into clinical supplies and commercial availability.
Join experts for a discussion on how contracting with a single service provider can offer significant benefits to the customer through:
- Integrated expertise between the formulation development teams, the manufacturing teams, clinical supply specialists, and the packaging teams
- Consistent exchange of information between the teams and retention of critical product knowledge gained over time
- Flexibility of selection of dosage form based on a wide variety of technologies
- Time and cost-saving benefits of integrated offerings and streamlined communications
Key Learning Objectives:
- Identify opportunities to streamline product development and shorten timelines
- Explore strategies to reduce the risk of avoidable delays during product development
- Understand how dosage form selection can shape future decisions and project trajectory
- Understand the pros and cons of working with a single integrated provider
Speakers: Lisa Caralli, Director, Science & Technology, Catalent
Ann McMahon, Customer Service Excellence Manager, Catalent
Time and date: Tuesday, Sept. 24, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after airing until Sept. 24, 2020
Sponsor: Catalent
Register free:
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Complying with International Pharmacopoeias
4
Q&A: Patient-Centric Drug Development Should Start at Product Definition
5